Clearside Biomedical Performance
| CLSDDelisted Stock | USD 0.41 0.16 28.07% |
The firm shows a Beta (market volatility) of 1.02, which signifies a somewhat significant risk relative to the market. Clearside Biomedical returns are very sensitive to returns on the market. As the market goes up or down, Clearside Biomedical is expected to follow. At this point, Clearside Biomedical has a negative expected return of -5.68%. Please make sure to confirm Clearside Biomedical's jensen alpha and the relationship between the value at risk and day typical price , to decide if Clearside Biomedical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Clearside Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 28.9 M | |
| Total Cashflows From Investing Activities | -638 K |
Clearside |
Clearside Biomedical Relative Risk vs. Return Landscape
If you would invest 409.00 in Clearside Biomedical on October 19, 2025 and sell it today you would lose (368.00) from holding Clearside Biomedical or give up 89.98% of portfolio value over 90 days. Clearside Biomedical is currently does not generate positive expected returns and assumes 14.5912% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Clearside, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clearside Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearside Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clearside Biomedical, and traders can use it to determine the average amount a Clearside Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3893
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLSD |
Based on monthly moving average Clearside Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clearside Biomedical by adding Clearside Biomedical to a well-diversified portfolio.
Clearside Biomedical Fundamentals Growth
Clearside Stock prices reflect investors' perceptions of the future prospects and financial health of Clearside Biomedical, and Clearside Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearside Stock performance.
| Return On Equity | -13.1 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (35.02) % | |||
| Current Valuation | (2.33 M) | |||
| Shares Outstanding | 5.23 M | |||
| Price To Earning | 130.00 X | |||
| Price To Book | 3.93 X | |||
| Price To Sales | 0.64 X | |||
| Revenue | 1.66 M | |||
| EBITDA | (24.35 M) | |||
| Cash And Equivalents | 29.03 M | |||
| Cash Per Share | 0.48 X | |||
| Total Debt | 52.47 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | (10.31) X | |||
| Cash Flow From Operations | (24.7 M) | |||
| Earnings Per Share | (5.11) X | |||
| Total Asset | 25.13 M | |||
| Retained Earnings | (355.27 M) | |||
| Current Asset | 20.48 M | |||
| Current Liabilities | 5.2 M | |||
About Clearside Biomedical Performance
By analyzing Clearside Biomedical's fundamental ratios, stakeholders can gain valuable insights into Clearside Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Clearside Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Clearside Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Clearside Biomedi operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.Things to note about Clearside Biomedical performance evaluation
Checking the ongoing alerts about Clearside Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearside Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clearside Biomedical is not yet fully synchronised with the market data | |
| Clearside Biomedical generated a negative expected return over the last 90 days | |
| Clearside Biomedical has high historical volatility and very poor performance | |
| Clearside Biomedical has some characteristics of a very speculative penny stock | |
| Clearside Biomedical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.66 M. Net Loss for the year was (34.35 M) with profit before overhead, payroll, taxes, and interest of 2.93 M. | |
| Clearside Biomedical currently holds about 29.03 M in cash with (24.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company shares are held by company insiders |
- Analyzing Clearside Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearside Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Clearside Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearside Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearside Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearside Biomedical's stock. These opinions can provide insight into Clearside Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Clearside Stock
If you are still planning to invest in Clearside Biomedical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clearside Biomedical's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |